Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
7.44 ^USD	-0.40%		-1.59%	+26.53%

05-07	Cogent Biosciences Q1 Loss Widens	MT
05-07	Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Unum Therapeutics Inc. Plans to Reduce its Current Workforce; Announces Resignation of Seth Ettenberg as Chief Scientific Officer

March 02, 2020 at 01:45 pm

Unum Therapeutics Inc. plans to reduce its current workforce by 43 employees (approximately 60%) to focus efforts on the BOXR1030 program.

The company also announced that its Chief Scientific Officer, Seth Ettenberg, Ph.D., has resigned after five years of service to the company.

Latest news about Cogent Biosciences, Inc.

Cogent Biosciences Q1 Loss Widens	05-07	MT
Cogent Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-07	CI
North American Morning Briefing : Stock Futures -2-	02-27	DJ
Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	02-26	MT
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-26	CI
Cogent Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-26	CI
Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14	02-26	MT
Transcript : Cogent Biosciences, Inc. - Special Call	02-23
Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating	02-23	MT
Cogent Biosciences Announces Positive Part 1B Data from Summit Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	02-22	CI
Top Midday Gainers	02-14	MT
Cogent Biosciences Launches $225 Million Private Placement; Shares Jump	02-14	MT
Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target	02-08	MT
Transcript : Cogent Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM	01-10
Cogent Biosciences Expects Certain Milestones for Bezuclastinib Trials in 2024	01-09	MT
HC Wainwright Adjusts Price Target on Cogent Biosciences to $13 From $27, Keeps Buy Rating	12-15	MT
North American Morning Briefing : Traders Eye -2-	12-12	DJ
Sector Update: Health Care Stocks Higher Late Afternoon	12-11	MT
Top Midday Decliners	12-11	MT
Sector Update: Health Care Stocks Rise Monday Afternoon	12-11	MT
Cogent Biosciences Says Phase 2 Trial of Bezuclastinib Showed 4 Related Serious Adverse Events; Shares Down	12-11	MT
Cogent Biosciences, Inc. Announces Positive Initial Data from the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezculastinib in Patients with Advanced Systemic Metocytosis	12-11	CI
Transcript : Cogent Biosciences, Inc. - Special Call	12-11
Cogent Biosciences Announces Positive Data from Part 1 of the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis	12-11	CI
Wedbush Downgrades Cogent Biosciences to Neutral From Outperform, Cuts Price Target to $5 From $20	12-11	MT

Chart Cogent Biosciences, Inc.

Duration

Period

More charts

Company Profile

Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Companyâs clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3KÎ±. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Sector

Biotechnology & Medical Research

Calendar

01/06/2024 - American Society of Clinical Oncology Annual Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.44 USD

Average target price

17.18 USD

Spread / Average Target

+130.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COGENT BIOSCIENCES, INC.	+26.53%	711M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.87B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs